ALLMedicine™ Atopic Dermatitis Center

Aug 16th, 2022 - To infect its human host, herpes simplex virus 1 (HSV-1) must overcome the protective barriers of skin and mucosa. Here, we addressed whether pathological skin conditions can facilitate viral entry via the skin surface and used ex vivo infection s...

Aug 13th, 2022 - Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always ...

Aug 13th, 2022 - Regular moisturizing with over-the-counter (OTC) treatments is considered a cornerstone of atopic dermatitis (AD) management regardless of disease severity, but OTC moisturizers are not an eligible product under most state Medicaid benefits, inclu...

Aug 13th, 2022 - There is no consensus on a treatment strategy for spinal giant cell tumor of bone (GCTB) because of the difficulty in their treatment. Treatment options often include the use of the controversial denosumab, an antibody therapy aimed at tumor shrin...

Aug 13th, 2022 - Approximately 8-9% of the world's population is affected by autoimmune diseases, and yet the mechanism of autoimmunity trigger is largely understudied. Two unique cell death modalities, ferroptosis and pyroptosis, provide a new perspective on the ...

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

Aug 12th, 2022 - This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subj...

Aug 12th, 2022 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately...

Aug 12th, 2022 - The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception) of the investigat...

Aug 12th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

Aug 12th, 2022 - The main purpose of this phase 2 study is to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Aug 12th, 2022 - Dupilumab dose reduction appears feasible in patients with controlled atopic dermatitis (AD) who have been on the monoclonal antibody therapy for at least 1 year, according to a recent study. The researchers suggest that the findings, published in...

Aug 12th, 2022 - I was quite sure I had multiple sclerosis when I was a medical student. I first noticed symptoms during my neurology rotation. All the signs were there: Fatigue that was getting worse in the North Carolina heat (Uhthoff sign!). A tingle running do...

Aug 11th, 2022 - The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) improves signs and symptoms of moderate to severe atopic dermatitis (AD) in patients who fail or cannot tolerate cyclosporine, according to a phase 3 study published in the British Journ...

Aug 8th, 2022 - Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis (AD) is truly a fascinating disease! Despite the thousands of scientific manuscripts published on AD, more novel insights keep coming about the clinical manifestations and risk factors of this co.